Roivant Sciences (NASDAQ:ROIV) CEO Eric Venker Sells 200,000 Shares of Stock

Roivant Sciences Ltd. (NASDAQ:ROIV) CEO Eric Venker sold 200,000 shares of the company’s stock in a transaction on Tuesday, November 3rd. The stock was sold at an average price of $36.31, for a total value of $7,262,000.00. Following the sale, the chief executive officer owned 999,154 shares of the company’s stock, valued at $36,279,281.74. This trade represents a 16.68% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Eric Venker also recently made the following trade(s):

• On Wednesday, October 28th, Eric Venker sold 200,000 shares of Roivant Sciences stock. The shares were sold at an average price of $36.59, for a total transaction of $7,318,000.00.
• On Tuesday, October 20th, Eric Venker sold 200,000 shares of Roivant Sciences stock. The stock was sold at an average price of $35.11, for a total transaction of $7,022,000.00.
• On Wednesday, September 30th, Eric Venker sold 200,000 shares of Roivant Sciences stock. The stock was sold at an average price of $36.62, for a total transaction of $7,324,000.00.
• On Friday, August 28th, Eric Venker sold 200,000 shares of Roivant Sciences stock. The stock was sold at an average price of $35.77, for a total transaction of $7,154,000.00.

Roivant Sciences Stock Performance

NASDAQ:ROIV opened at $36.62 on Friday. The firm has a market cap of $26.45 billion, a price-to-earnings ratio of -69.09 and a beta of 1.23. Roivant Sciences Ltd. has a 52 week low of $19.79 and a 52 week high of $42.50. The firm has a 50-day moving average price of $36.66 and a two-hundred day moving average price of $31.72.

Roivant Sciences (NASDAQ:ROIV) last announced its earnings results on Friday, August 7th. The company reported ($0.26) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.04. The firm had revenue of $1.44 million for the quarter, compared to the consensus estimate of $2.06 million. Roivant Sciences had a negative return on equity of 22.94% and a negative net margin of 3,534.96%. As a group, sell-side analysts forecast that Roivant Sciences Ltd. will post -2.00 earnings per share for the current year.

Institutional Trading of Roivant Sciences

Institutional investors have recently modified their holdings of the business. Wellington Management Group LLP increased its position in shares of Roivant Sciences by 179.0% in the second quarter. Wellington Management Group LLP now owns 2,687,870 shares of the company’s stock worth $95,124,000 after purchasing an additional 1,724,588 shares during the last quarter. Maverick Capital Ltd. bought a new stake in Roivant Sciences in the first quarter worth $45,066,000. Assenagon Asset Management S.A. lifted its stake in Roivant Sciences by 18.2% in the second quarter. Assenagon Asset Management S.A. now owns 8,362,952 shares of the company’s stock worth $295,965,000 after purchasing an additional 1,286,464 shares during the last quarter. Affinity Asset Advisors LLC lifted its stake in Roivant Sciences by 64.7% in the first quarter. Affinity Asset Advisors LLC now owns 2,800,000 shares of the company’s stock worth $77,560,000 after purchasing an additional 1,100,000 shares during the last quarter. Finally, Sumitomo Mitsui Trust Group Inc. purchased a new stake in Roivant Sciences during the third quarter valued at about $35,624,000. 64.76% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

ROIV has been the topic of several research analyst reports. Bank of America reissued a “neutral” rating on shares of Roivant Sciences in a research report on Friday, July 31st. HC Wainwright boosted their target price on Roivant Sciences from $41.00 to $47.00 and gave the company a “buy” rating in a research note on Tuesday, September 8th. UBS Group set a $55.00 price target on Roivant Sciences in a research report on Wednesday, September 9th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Roivant Sciences in a research note on Wednesday, August 19th. Finally, Wolfe Research lowered Roivant Sciences from an “outperform” rating to a “peer perform” rating in a report on Monday, October 12th. One equities research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $46.55.

Roivant Sciences Company Profile

Roivant Sciences Ltd. (NASDAQ: ROIV) is a biopharmaceutical company focused on discovering, developing and commercializing medicines. The company organizes its activities through subsidiaries and partner companies, often referred to as “Vants,” which specialize in particular therapeutic areas and stages of drug development.

Roivant’s research and development activities have included immunology, dermatology, women’s health, rare diseases and other specialty-care fields. Its portfolio has included Vtama (tapinarof) cream, a nonsteroidal topical treatment approved in the United States for plaque psoriasis and atopic dermatitis.